Review ArticleClinical Review

Cushing Syndrome: Maybe Not So Uncommon of an Endocrine Disease

Federica Guaraldi and Roberto Salvatori
The Journal of the American Board of Family Medicine March 2012, 25 (2) 199-208; DOI: https://doi.org/10.3122/jabfm.2012.02.110227

References

  1. 1.↵
    1. Arnaldi G,
    2. Angeli A,
    3. Atkinson AB,
    4. et al
    . Diagnosis and complications of Cushing syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593–602.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Reincke M
    . Subclinical Cushing syndrome. Endocrinol Metab Clin North Am 2000;29:43–56.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kloos RT,
    2. Gross MD,
    3. Francis IR,
    4. Korobkin M,
    5. Shapiro B
    . Incidentally discovered adrenal masses. Endocr Rev 1995;16:460–84.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    National Institutes of Health, Office of Rare Diseases Research. Rare Diseases and Related Terms. http://rarediseases.info.nih.gov/RareDiseaseList.aspx?PageID=1. Accessed January 25, 2012.
  5. 5.↵
    1. Faglia G,
    2. Beck-Peccoz P,
    3. Ambrosi B,
    4. Travaglini P,
    5. Spada A
    1. Ambrosi B,
    2. Faglia G
    ; Multicenter Pituitary Tumor Study Group. Epidemiology of pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds.). Pituitary Adenomas: New Trends in Basic and Clinical Research. Amsterdam: Excerpta Medica; 1991:159–68.
  6. 6.↵
    1. Etxabe J,
    2. Vazquez JA
    . Morbidity and mortality in Cushing disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994;40:479–84.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Lindholm J,
    2. Juul S,
    3. Jorgensen JO,
    4. et al
    . Incidence and late prognosis of Cushing syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117–23.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Anderson GH Jr.,
    2. Blakeman N,
    3. Streeten DH
    . The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609–15.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Catargi B,
    2. Rigalleau V,
    3. Poussin A,
    4. et al
    . Occult Cushing syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003;88:5808–13.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Chiodini I,
    2. Torlontano M,
    3. Scillitani A,
    4. et al
    . Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case–control study in hospitalized patients. Eur J Endocrinol 2005;153:837–44.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Chiodini I,
    2. Mascia ML,
    3. Muscarella S,
    4. et al
    . Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 2007;147:541–8.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Omura M,
    2. Saito J,
    3. Yamaguchi K,
    4. Kakuta Y,
    5. Nishikawa T
    . Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004;27:193–202.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Tabarin A,
    2. Perez P
    . Pros and cons of screening for occult Cushing syndrome. Nat Rev Endocrinol 2011;7:445–55.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Nieman LK,
    2. Biller BM,
    3. Findling JW,
    4. et al
    . The diagnosis of Cushing syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526–40.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Hamrahian AH,
    2. Ioachimescu AG,
    3. Remer EM,
    4. et al
    . Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005;90:871–7.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Grumbach MM,
    2. Biller BM,
    3. Braunstein GD,
    4. et al
    . Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003;138:424–9.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Yanovski JA,
    2. Cutler GB Jr.
    . Glucocorticoid action and the clinical features of Cushing syndrome. Endocrinol Metab Clin North Am 1994;23:487–509.
    OpenUrlPubMedWeb of Science
  18. 18.↵
    1. Chan KC,
    2. Lit LC,
    3. Law EL,
    4. et al
    . Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem 2004;50:757–9.
    OpenUrlFREE Full Text
  19. 19.↵
    1. Mericq MV,
    2. Cutler GB Jr.
    . High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab 1998;83:682–4.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Newell-Price J,
    2. Bertagna X,
    3. Grossman AB,
    4. Nieman LK
    . Cushing syndrome. Lancet 2006;367:1605–17.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Garde AH,
    2. Hansem AM
    . Long-term stability of salivary cortisol Scan J Clin Lab Invest 2005;65(5):433–6.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Badrick E,
    2. Kirschbaum C,
    3. Kumari M
    . The relationship between smoking status and cortisol secretion. J Clin Endocrinol Metab 2007;92:819–24.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Papanicolaou DA,
    2. Mullen N,
    3. Kyrou I,
    4. Nieman LK
    . Nighttime salivary cortisol: a useful test for the diagnosis of Cushing syndrome. J Clin Endocrinol Metab 2002;87:4515–21.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Baid SK,
    2. Sinaii N,
    3. Wade M,
    4. Rubino D,
    5. Nieman LK
    . Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism. J Clin Endocrinol Metab 2007;92:3102–7.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Wood PJ,
    2. Barth JH,
    3. Freedman DB,
    4. Perry L,
    5. Sheridan B
    . Evidence for the low dose dexamethasone suppression test to screen for Cushing syndrome: recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997;34:222–9.
    OpenUrlPubMedWeb of Science
  26. 26.↵
    1. Putignano P,
    2. Kaltsas GA,
    3. Satta MA,
    4. Grossman AB
    . The effects of anti-convulsant drugs on adrenal function. Horm Metab Res 1998;30:389–97.
    OpenUrlPubMedWeb of Science
  27. 27.↵
    1. Nickelsen T,
    2. Lissner W,
    3. Schöffling K
    . The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol 1989;94:275–80.
    OpenUrlPubMed
  28. 28.↵
    1. Elamin MB,
    2. Murad MH,
    3. Mullan R,
    4. et al
    . Accuracy of diagnostic tests for Cushing syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008;93:1553–62.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Mantero F,
    2. Terzolo M,
    3. Arnaldi G,
    4. et al
    . A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637–44.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Ezzat S,
    2. Asa SL,
    3. Couldwell WT,
    4. et al
    . The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613–9.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Nieman LK,
    2. Oldfield EH,
    3. Wesley R,
    4. Chrousos GP,
    5. Loriaux DL,
    6. Cutler GB Jr.
    . A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing syndrome. J Clin Endocrinol Metab 1993;77:1308–12.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Reimondo G,
    2. Paccotti P,
    3. Minetto M,
    4. et al
    . The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing syndrome. Clin Endocrinol (Oxf) 2003;58:718–24.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Lindsay JR,
    2. Nieman LK
    . Differential diagnosis and imaging in Cushing syndrome. Endocrinol Metab Clin North Am 2005;34:403–21.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Oldfield EH,
    2. Doppman JL,
    3. Nieman LK,
    4. et al
    . Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing syndrome. N Engl J Med 1991;325:897–905.
    OpenUrlPubMedWeb of Science
  35. 35.↵
    1. Biller BM,
    2. Grossman AB,
    3. Stewart PM,
    4. et al
    . Treatment of adrenocorticotropin-dependent Cushing syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454–62.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Guerrieri M,
    2. Campagnacci R,
    3. Patrizi A,
    4. Romiti C,
    5. Arnaldi G,
    6. Boscaro M
    . Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. Surg Endosc 2010;24:2542–6.
    OpenUrlPubMed
  37. 37.↵
    1. Toniato A,
    2. Merante-Boschin I,
    3. Opocher G,
    4. Pelizzo MR,
    5. Schiavi F,
    6. Ballotta E
    . Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009;249:388–91.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Chiodini I,
    2. Morelli V,
    3. Salcuni AS,
    4. et al
    . Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010;95:2736–45.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Iacobone M,
    2. Albiger N,
    3. Scaroni C,
    4. et al
    . The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 2008;32:882–9.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Mazzuco TL,
    2. Bourdeau I,
    3. Lacroix A
    . Adrenal incidentalomas and subclinical Cushing syndrome: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes 2009;16:203–10.
    OpenUrlPubMed
  41. 41.↵
    1. Hammer GD,
    2. Tyrrell JB,
    3. Lamborn KR,
    4. et al
    . Transsphenoidal microsurgery for Cushing disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004;89:6348–57.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Rees DA,
    2. Hanna FW,
    3. Davies JS,
    4. Mills RG,
    5. Vafidis J,
    6. Scanlon MF
    . Long-term follow-up results of transsphenoidal surgery for Cushing disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 2002;56:541–51.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Fleseriu M,
    2. Biller BM,
    3. Findling J,
    4. et al
    . Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with refractory cushing syndrome: results from the Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome (SEISMIC). Endocr Rev 2011;32:OR09–5.
    OpenUrl
  44. 44.↵
    1. Petrossians P,
    2. Thonnard A-S,
    3. Beckers A
    . Medical treatment in Cushing syndrome: dopamine agonists and cabergoline. Neuroendocrinology 2010;92(Suppl 1):116–9.
    OpenUrlPubMed
  45. 45.↵
    1. Colao A,
    2. Petersenn S,
    3. Newell-Price J,
    4. et al
    . Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, Phase III Study. Endocr Rev 2011;32:abst OR09–6.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section